A Phase II trial of KarXT (Trospium chloride/Xanomeline) for the treatment of schizophrenia

Trial Profile

A Phase II trial of KarXT (Trospium chloride/Xanomeline) for the treatment of schizophrenia

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs Trospium chloride/xanomeline (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Dec 2016 New trial record
    • 15 Dec 2016 According to a Karuna Pharmaceuticals media release, company intends to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top